Owner Investor / Financier Operator Developer Offtaker
GlaxoSmithKline plc (GSK) is a global biopharmaceutical company headquartered in the United Kingdom. The company researches, develops, manufactures, and markets vaccines and specialty medicines, with core areas including infectious diseases, HIV (through majority-owned ViiV Healthcare), respiratory and immunology, and oncology. GSK operates extensive R&D programs and clinical development activities supported by a worldwide network of laboratories and regulatory engagements. In 2022, it demerged its consumer healthcare business into Haleon, focusing GSK on prescription medicines and vaccines.
For the chemical and life sciences value chain, GSK’s operations span small-molecule synthesis, biologics, and large-scale vaccine production, encompassing active pharmaceutical ingredient (API) and intermediate manufacturing for its own products, formulation, and fill-finish capabilities. The company maintains global manufacturing sites and supply chains adhering to GMP and other international quality standards, and collaborates with partners and institutions to advance new therapies and improve production reliability.
Also known as GlaxoSmithKline.
chemXplore tracks 4 projects involving GSK, of which one is active.
Besides this one, the record holds 3 completed projects.
Closest to start-up first.
The 3 that are completed, on hold or cancelled are in the record. See all 4 in chemXplore →
Phase Ib BEHOLD‑1 reports durable responses and 11.1‑month median PFS at the selected phase III dose; safety predominantly haematologic with most grade ≥3 events.
FDA approves a six-month antisense-oligonucleotide therapy with option for self-administration; phase III showed 19% functional cure in patients with HBsAg ≤3000 IU/ml.
First FDA‑approved immunotherapy for this biomarker-defined rectal cancer; AZUR-1 shows high sustained clinical complete response rates and no recurrences among responders.
Phase Ib shows 61% ORR at 8 mg/kg with manageable safety; data supported selection of 8 mg/kg for the ongoing global phase III EMBOLD SCLC‑301.
More than 20 abstracts across lung, gynaecological and gastrointestinal cancers, including positive Ris‑Rez ES‑SCLC activity, Mo‑Rez durable responses in platinum‑resistant ovarian cancer, and Jemperli complete responses in MSI‑H rectal cancer.
Long-acting cabotegravir + rilpivirine achieved superior viral suppression versus standard oral ART at six months when initiated in people with detectable HIV.
Trispecific TCE binds T cells and two tumour antigens; entering Phase I in 2027; deal worth up to $750 million; designed to improve efficacy and tolerability versus current TCEs.
Phase I/II ARROS‑1 data show 94% ORR, 90% progression‑free at 12 months and strong intracranial activity; supplemental US submission planned for 2026.
active all projects
